טוען...
Immune checkpoint pathways in non-small cell lung cancer
Immunotherapy has evolved at a phenomenal pace in cancer therapeutics. This has primarily been fueled by the much perceived necessity to procure an alternative to current standard of care chemotherapy agents, owing to several concerns such as treatment-related toxicity and poor long-term survival as...
שמור ב:
| הוצא לאור ב: | Ann Transl Med |
|---|---|
| Main Authors: | , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
AME Publishing Company
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5890048/ https://ncbi.nlm.nih.gov/pubmed/29666811 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/atm.2017.09.30 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|